Update on FDA Advisory Committee Vote on Camizestrant in Combination with a CDK4/6 Inhibitor for Advanced HR-Positive Breast Cancer
Summary
The US Food and Drug Administration s (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of Astr
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.